Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.

Exelixis is best known for its discovery of cabozantinib, a tyrosine kinase inhibitor (TKI) that was approved in 2012 for medullary thyroid cancer (MTC). This small molecule was later approved for ...